Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy
暂无分享,去创建一个
L B Sheiner | T F Blaschke | D Verotta | T. Blaschke | L. Sheiner | A. Collier | D. Verotta | R. Coombs | A C Collier | J M Gries | R Coombs | G F Vanhove | J. Gries | G. Vanhove | Ann C. Collier | Robert W. Coombs | J. Gries | Davide Verotta | Lewis B. Sheiner | Terrence F. Blaschke
[1] M. Hirsch,et al. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro. , 1992, The Journal of infectious diseases.
[2] A. Gerber,et al. 1994 revised guidelines for the performance of CD4+ T-cell determinations in persons with human immunodeficiency virus (HIV) infections , 1994 .
[3] T. Blaschke,et al. Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy , 1997, Antimicrobial agents and chemotherapy.
[4] Bradley Efron,et al. The Effect of High-Dose Saquinavir on Viral Load and CD4+ T-Cell Counts in HIV-Infected Patients , 1996, Annals of Internal Medicine.
[5] B. Irvine,et al. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[6] J. Bremer,et al. Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories , 1992, Journal of clinical microbiology.
[7] D. Katzenstein,et al. Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial. , 1995, The Journal of infectious diseases.
[8] T. Merigan,et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. , 1996, The New England journal of medicine.
[9] P. Volberding,et al. Zidovudine response relationships in early human immunodeficiency virus infection , 1993, Clinical pharmacology and therapeutics.
[10] A. Pesce,et al. Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity , 1994, AIDS.
[11] R. Tibshirani,et al. Generalized Additive Models , 1991 .
[12] J. Craig,et al. Antiviral Synergy between Inhibitors of HIV Proteinase and Reverse Transcriptase , 1993 .
[13] A. Pesce,et al. Concentrations of Phosphorylated Zidovudine (ZDV) in Patient Leukocytes Do Not Correlate with ZDV Dose or Plasma Concentrations , 1991, Therapeutic drug monitoring.